Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Silence Therapeutics (SLN) over the last 6 years, with Q2 2025 value amounting to $1000.0.

  • Silence Therapeutics' Cash from Financing Activities fell 9990.65% to $1000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$83000.0, marking a year-over-year decrease of 10005.38%. This contributed to the annual value of $142.1 million for FY2024, which is 34489.78% up from last year.
  • Silence Therapeutics' Cash from Financing Activities amounted to $1000.0 in Q2 2025, which was down 9990.65% from $14000.0 recorded in Q1 2025.
  • Silence Therapeutics' Cash from Financing Activities' 5-year high stood at $133.0 million during Q1 2024, with a 5-year trough of -$98000.0 in Q4 2024.
  • Its 5-year average for Cash from Financing Activities is $15.7 million, with a median of $585897.9 in 2021.
  • Data for Silence Therapeutics' Cash from Financing Activities shows a peak YoY increase of 57587672.87% (in 2024) and a maximum YoY decrease of 10079.6% (in 2024) over the last 5 years.
  • Over the past 5 years, Silence Therapeutics' Cash from Financing Activities (Quarter) stood at $585897.9 in 2021, then crashed by 91.19% to $51608.8 in 2022, then surged by 23756.82% to $12.3 million in 2023, then tumbled by 100.8% to -$98000.0 in 2024, then skyrocketed by 101.02% to $1000.0 in 2025.
  • Its Cash from Financing Activities stands at $1000.0 for Q2 2025, versus $14000.0 for Q1 2025 and -$98000.0 for Q4 2024.